Arabidopsis Hormone Database: a comprehensive genetic and phenotypic information database for plant hormone research in Arabidopsis

Plant hormones are small organic molecules that influence almost every aspect of plant growth and development. Genetic and molecular studies have revealed a large number of genes that are involved in responses to numerous plant hormones, including auxin, gibberellin, cytokinin, abscisic acid, ethylene, jasmonic acid, salicylic acid, and brassinosteroid. Here, we develop an Arabidopsis hormone database, which aims to provide a systematic and comprehensive view of genes participating in plant hormonal regulation, as well as morphological phenotypes controlled by plant hormones. Based on data from mutant studies, transgenic analysis and gene ontology (GO) annotation, we have identified a total of 1026 genes in the Arabidopsis genome that participate in plant hormone functions. Meanwhile, a phenotype ontology is developed to precisely describe myriad hormone-regulated morphological processes with standardized vocabularies. A web interface (http://ahd.cbi.pku.edu.cn) would allow users to quickly get access to information about these hormone-related genes, including sequences, functional category, mutant information, phenotypic description, microarray data and linked publications. Several applications of this database in studying plant hormonal regulation and hormone cross-talk will be presented and discussed

Factors associated with parental acceptance of influenza vaccination for their children: the evidence from four cities of China

Background It is necessary and urgent to vaccinate 245 million Chinese children against influenza pandemics. The main purpose of this study was to evaluate different psychological and demographic factors that influence parental willingness to vaccinate their children against influenza. Methods A hybrid theoretical framework was expanded and verified with 462 sample data collected from four cities in China. Structural equation models were used to test nine theoretical hypotheses, and the non-standardized coefficient method was used to discuss the moderating effects among demographic variables. Results Knowledge is considered to be the significant factor of performance expectancy (β = 0.228), effort expectancy (β = 0.227) and perceived risk (β = −0.138), and social influence also has the significant impacts on the above three variables, with β values of 0.437, 0.386, and −0.172. Performance expectancy (β = 0.402), effort expectancy (β = 0.343), and perceived risk (β = −0.244) thus significantly affect parental behavioral intention regarding children’s influenza vaccination. Gender, education, and kids’ gender are demographic variables with significant moderating effects, while age, income, number of kids are not significant. Conclusion To improve the acceptability of influenza vaccination among Chinese children, the promoting policies should emphasize on public knowledge and social influence, as well as effectiveness, affordability, and safety of vaccination

Estimating the Fractional Cycle Biases for GPS Triple-Frequency Precise Point Positioning with Ambiguity Resolution Based on IGS Ultra-Rapid Predicted Orbits

We investigate the estimation of the fractional cycle biases (FCBs) for GPS triple-frequency uncombined precise point positioning (PPP) with ambiguity resolution (AR) based on the IGS ultra-rapid predicted (IGU) orbits. The impact of the IGU orbit errors on the performance of GPS triple-frequency PPP AR is also assessed. The extra-wide-lane (EWL), wide-lane (WL) and narrow-lane (NL) FCBs are generated with the single difference (SD) between satellites model using the global reference stations based on the IGU orbits. For comparison purposes, the EWL, WL and NL FCBs based on the IGS final precise (IGF) orbits are estimated. Each of the EWL, WL and NL FCBs based on IGF and IGU orbits are converted to the uncombined FCBs to implement the static and kinematic triple-frequency PPP AR. Due to the short wavelengths of NL ambiguities, the IGU orbit errors significantly impact the precision and stability of NL FCBs. An average STD of 0.033 cycles is achieved for the NL FCBs based on IGF orbits, while the value of the NL FCBs based on IGU orbits is 0.133 cycles. In contrast, the EWL and WL FCBs generated based on IGU orbits have comparable precision and stability to those generated based on IGF orbits. The use of IGU orbits results in an increased time-to-first-fix (TTFF) and lower fixing rates compared to the use of IGF orbits. Average TTFFs of 23.3 min (static) and 31.1 min (kinematic) and fixing rates of 98.1% (static) and 97.4% (kinematic) are achieved for the triple-frequency PPP AR based on IGF orbits. The average TTFFs increase to 27.0 min (static) and 37.9 min (kinematic) with fixing rates of 97.0% (static) and 96.3% (kinematic) based on the IGU orbits. The convergence times and positioning accuracy of PPP and PPP AR based on IGU orbits are slightly worse than those based on IGF orbits. Additionally, limited by the number of satellites transmitting three frequency signals, the introduction of the third frequency, L5, has a marginal impact on the performance of PPP and PPP AR. The GPS triple-frequency PPP AR performance is expected to improve with the deployment of new-generation satellites capable of transmitting the L5 signal

Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis

Background/Aims: Whether patients with RAS mutation metastatic colorectal cancer (mCRC) obtain benefits from bevacizumab added to first-line chemotherapy remains unclear. Methods: PubMed, Cochrane Systematic Reviews, the Cochrane Collaboration Central Register of Controlled Clinical Trials, ClinicalTrials.gov, and the American Society of Clinical Oncology and European Society for Medical Oncology databases were searched to identify abstracts for randomized controlled trials (RCTs) evaluating the efficacy of bevacizumab for the first-line treatment of patients with RAS mutations mCRC from inception to the end of April 2016. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were estimated. Results: Ten eligible papers reporting six RCTs were included. In the network meta-analysis of patients with RAS mutations, bevacizumab + chemotherapy prolonged PFS compared with chemotherapy alone (HR 0.75, 95% CI 0.51-1.10), but the difference was not statistically significant. Bevacizumab + chemotherapy did not prolong OS compared with chemotherapy alone (HR 1.10, 95% CI 0.73-1.66). Conclusion: There was insufficient evidence to definitively state that patients with RAS mutations mCRC could benefit from bevacizumab combined with chemotherapy as first-line treatment

CXCL6 promotes human hepatocyte proliferation through CXCR1-NFκB pathway and inhibits collagen I secretion by hepatic stellate cells

Hepatocyte proliferation and collagen I (COLI) secretion are important processes during liver regeneration. This study aimed to investigate the role of CXCL6 in hepatocyte proliferation and COLI secretion. Serum CXCL6 level in chronic hepatitis B (CHB) patients were examined and the effects of CXCL6 on the proliferation of L02 hepatocytes and the secretion of COLI from LX2 human hepatic stellate cells were evaluated. We found that serum CXCL6 level increased gradually with disease progression of CHB, and there was positive correlation between serum CXCL6 level and alanine transaminase (ALT) and aspartate transaminase (AST). In vitro, CXCL6 significantly promoted L02 proliferation but this was blocked upon CXCR1 knockdown. NF-κB was upregulated by CXCL6 but downregulated by CXCR1 siRNA in L02 cells. CXCL6 inhibited the secretion of COLI by LX2 cells, dependent on CXCR1 and CXCR2. Taken together, these data suggest that increased expression of CXCL6 during CHB could promote hepatocyte proliferation through CXCR1/NF-κB pathway and inhibit the secretion of COLI by hepatic stellate cells.The accepted manuscript in pdf format is listed with the files at the bottom of this page. The presentation of the authors' names and (or) special characters in the title of the manuscript may differ slightly between what is listed on this page and what is listed in the pdf file of the accepted manuscript; that in the pdf file of the accepted manuscript is what was submitted by the author

Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis

<div><p>Background</p><p>Platinum-based standard chemotherapy improves survival of ovarian cancer (OC), but the five-year survival rate remains below 50%. Antiangiogenic agents (7.5 or 15 mg/kg Bevacizumab, Bev) plus to standard chemotherapy improve progression-free survival (PFS) not overall survival (OS) in completed randomized controlled trials (RCTs). The efficacy and safety of two doses of Bev + standard chemotherapy remain controversial.</p> <p>Methods</p><p>MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane databases and <a href="http://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> were searched. The outcomes of eligible RCTs included PFS, OS and toxicities. Hazard ratio (HR) and relative risk (RR) were used for the meta-analysis and were expressed with 95% confidence intervals (CIs).</p> <p>Results</p><p>Bev + chemotherapy improved PFS (HR, 0.82; 95% CI, 0.75 to 0.89; <i>P</i> = .000) and OS (HR, 0.87; 95% CI, 0.77 to 0.99; <i>P</i> = .026) in newly diagnosed OC (2 trials, 2776 patients), and PFS (HR, 0.48; 95% CI, 0.41 to 0.57; <i>P</i> = .000) in recurrent OC (2 trials, 845 patients). Bev + chemotherapy increased non-CNS bleeding (RR, 3.63; 95% CI, 1.81 to 7.29; <i>P</i> = .000), hypertension grade ≥ 2 (RR, 4.90; 95% CI, 3.83 to 6.25; <i>P</i> = .000), arterial thromboembolism (RR, 2.29; 95% CI, 1.33 to 3.94; <i>P</i> = .003), gastrointestinal perforation (RR, 2.90; 95% CI, 1.44 to 5.82; <i>P</i> = .003), and proteinuria grade ≥ 3 (RR, 6.63; 95% CI 3.17 to 13.88; <i>P</i> = .000). No difference was observed between the two Bev doses in PFS (HR, 1.04; 95% CI, 0.88 to 1.24) or OS (HR, 1.15, 95% CI, 0.88 to 1.50), but 15 mg/kg Bev increased toxicities.</p> <p>Conclusion</p><p>Bev + standard chemotherapy delayed progression for newly diagnosed and recurrent OC, and improved survival for newly diagnosed OC. The 7.5 mg/kg dose appeared to be optimal for newly diagnosed OC patients with high risk for progression.</p> </div

Cytokeratin19 positive hepatocellular carcinoma is associated with increased peritumoral ductular reaction

Background and aims. Cytokeratin19 positive (CK19+) hepatocellular carcinoma (HCC) is thought to derive from liver progenitor cells (LPC). However, whether peritumoralductular reaction (DR) differs between CK19+ and CK19 negative (CK19−) HCC patients remains unclear.Material and methods. One hundred and twenty HBV-related HCC patients were enrolled in this study. Clini-copathological variables were collected, and immunohistochemistry staining for CK19, proliferating cell nuclear antigen (PCNA), inter-leukin-6 (IL-6) and β-catenin were performed in tumor and peritumor liver tissues.Results. CK19+ HCC patients had higher grade of peritumoral DR and proportion of proliferative DR than the CK19- group. The mean number or the proportion of cytoplasmic β-catenin+ DR was higher in the CK19+ group than in the CK19− group. Furthermore, there were more patients with nuclear β-catenin+ peritumoral DR in the CK19+ group as compared to the CK19- group.Conclusion. Peritumoral DR was more abundant and proliferative in CK19+ HCC patients, with higher level of nuclear translocation of β-catenin. However, it is unclear whether peritumoral DR is the cause or result of poor prognosis in these patients

Small Molecule Supplements Improve Cultured Megakaryocyte Polyploidization by Modulating Multiple Cell Cycle Regulators

Platelets (PLTs) are produced by megakaryocytes (MKs) that completed differentiation and endomitosis. Endomitosis is an important process in which the cell replicates its DNA without cytokinesis and develops highly polyploid MK. In this study, to gain a better PLTs production, four small molecules (Rho-Rock inhibitor (RRI), nicotinamide (NIC), Src inhibitor (SI), and Aurora B inhibitor (ABI)) and their combinations were surveyed as MK culture supplements for promoting polyploidization. Three leukemia cell lines as well as primary mononuclear cells were chosen in the function and mechanism studies of the small molecules. In an optimal culture method, cells were treated with different small molecules and their combinations. The impact of the small molecules on megakaryocytic surface marker expression, polyploidy, proliferation, and apoptosis was examined for the best MK polyploidization supplement. The elaborate analysis confirmed that the combination of SI and RRI together with our MK induction system might result in efficient ploidy promotion. Our experiments demonstrated that, besides direct downregulation on the expression of cytoskeleton protein actin, SI and RRI could significantly enhance the level of cyclins through the suppression of p53 and p21. The verified small molecule combination might be further used in the in vitro PLT manufacture and clinical applications